Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones
06 janv. 2023 07h00 HE
|
Mersana Therapeutics, Inc.
Report top-line data from UPLIFT registrational trial in mid-2023, submit potential BLA around year end 2023, and prepare for potential U.S. commercial launch in 2024Advance Phase 3 UP-NEXT and Phase...
Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates
22 déc. 2022 16h05 HE
|
Mersana Therapeutics, Inc.
Collaboration focuses on discovering novel STING-agonist ADCs for up to two targets leveraging Mersana’s proprietary immunostimulatory platform Mersana to receive $30 million upfront payment, up to...
European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer
14 déc. 2022 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 déc. 2022 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present at Jefferies London Healthcare Conference
08 nov. 2022 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results
07 nov. 2022 07h00 HE
|
Mersana Therapeutics, Inc.
Completed enrollment in UPLIFT clinical trial; topline data expected mid-2023; potential Biologics License Application (BLA) submission anticipated by the end of 2023Initiated patient enrollment and...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 nov. 2022 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022
31 oct. 2022 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer
06 oct. 2022 16h05 HE
|
Mersana Therapeutics, Inc.
Topline data from UPLIFT expected in mid-2023Targeting potential Biologics License Application (BLA) submission by the end of 2023 CAMBRIDGE, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Mersana...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 oct. 2022 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...